Hepatotoxicity in hematologic malignancy and hematopoietic stem cell transplant patients receiving posaconazole or isavuconazole prophylaxis: a single-center cohort study. (PubMed, Antimicrob Steward Healthc Epidemiol) - Jul 18, 2026 - "In this retrospective analysis, no statistically significant difference in hepatotoxicity incidence was observed between isavuconazole and posaconazole for prophylaxis. Larger prospective studies are needed to confirm these findings and further define the hepatic safety profiles of these antifungal agents."
Journal • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Oncology • Transplantation
|
|
Courtney Nichols; Kelci Coe; Nikki Tran; Samantha Steele
|